Neptune Wellness Solutions Inc.
NEPTF Healthcare Drug Manufacturers Specialty & Generic
Revenue growth for five consecutive years, operating cash flow growth for five.
Follow NEPTF
Neptune Wellness Solutions Inc. (NEPTF) EV/Sales
As of 15 October 2026, Neptune Wellness Solutions Inc. (NEPTF) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.2× (June 2022) to 28.6× (July 2019); the current reading is higher than 25% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 0.5× | (37.81%) |
| FY2022 | 0.8× | (73.24%) |
| FY2021 | 3.1× | (27.74%) |
| FY2020 | 4.3× | (67.96%) |
| FY2019 | 13.5× | 103.52% |
| FY2018 | 6.6× | 153.39% |
| FY2017 | 2.6× | (46.71%) |
| FY2016 | 4.9× | (18.66%) |
| FY2016 | 6.0× | (27.84%) |
| FY2015 | 8.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | 1.1× | 113.49% |
| Sep 2023 | 0.5× | (6.02%) |
| Jun 2023 | 0.6× | 7.43% |
| Mar 2023 | 0.5× | 66.84% |
| 27 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SXTC China SXT Pharmaceuticals, Inc. compare | −5.9× |
| SBFM Sunshine Biopharma, Inc. compare | −0.3× |
| LSDIF Lucy Scientific Discovery Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| IMCC IM Cannabis Corp. compare | 0.0× |
| PTPI Petros Pharmaceuticals, Inc. compare | 0.4× |
| NEPTF Neptune Wellness Solutions Inc. | 1.1× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)